Replicate Study design for Brazil [Regulatives / Guidelines]

posted by Weidson – Brazil, 2018-05-22 20:51 (1244 d 06:46 ago) – Posting: # 18799
Views: 1,827

Dear balakotu

The ANVISA have adopted the EMA's Approach. However, for you use this approach you need to convince them that their drug is highly variable. I hope I have helped you.


Best Regards
Weidson C. de Souza


Edit: Post moved. [Helmut]

Complete thread:

Activity
 Admin contact
21,731 posts in 4,544 threads, 1,543 registered users;
online 19 (0 registered, 19 guests [including 4 identified bots]).
Forum time: Monday 03:38 CEST (Europe/Vienna)

Law is mind without reason.    Aristotle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5